drugset / Trial / NCT02036359
Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca
RandomizedParallel-groupOpen-labelTreatment
Summary
To compare clinical response (complete response and partial response) by RECIST) rates by RECIST between erlotinib monotherapy and docetaxel plus cisplatin chemotherapy
Timeline
- Start
- 2012-05
- Primary completion
- 2015-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Docetaxel | Small molecule | 35 mg/m2 | Intravenous |
| Comparator | Erlotinib | Small molecule | 150 mg | Oral |